Treatment patterns and outcomes in BRAF V600E‐mutant melanoma patients with brain metastases receiving vemurafenib in the real‐world setting

Publisher： John Wiley & Sons Inc

E-ISSN： 2045-7634|4|8|1205-1213

ISSN： 2045-7634

Source： Cancer Medicine, Vol.4, Iss.8, 2015-08, pp. : 1205-1213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vemurafenib and radiation therapy in melanoma brain metastases

By Narayana Ashwatha  

Journal of Neuro-Oncology, Vol. 113, Iss. 3, 2013-07 ,pp. : 411-416

Springer Publishing Company

Access to resources Recommend Favorite

BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAFV600E mutation

By Young Kate   Minchom Anna   Larkin James  

Future Oncology, Vol. 8, Iss. 5, 2012-05 ,pp. : 499-507

Future Medicine

Access to resources Recommend Favorite

Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients

By                

Oncology Letters, Vol. 10, Iss. 3, 2015-01 ,pp. : 1882-1888

Spandidos Publications

Access to resources Recommend Favorite

Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules

By              

Oncology Letters, Vol. 9, Iss. 6, 2015-01 ,pp. : 2633-2638

Spandidos Publications

Access to resources Recommend Favorite

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma

By  

Cancer Medicine, Vol. 7, Iss. 1, 2018-01 ,pp. : 95-104

John Wiley & Sons Inc

Access to resources Recommend Favorite